On June 02, 2014, Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that data from the Company’s Phase 1 study with GALE-301, or Folate Binding Protein (FBP), was presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Galena Biopharma Inc (NASDAQ:GALE), weekly performance is 20.18%. On last trading day company shares ended up $2.68. Analysts mean target price for the company is $6.88. Galena Biopharma Inc (NASDAQ:GALE), distance from 50-day simple moving average (SMA50) is 17.73%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares gained 6.34% to $16.10. The company on June 2 reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body’s natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX), advanced 7.40% in last trading session and ended the day on $16.26. CLDX, return on assets is -36.10%. Celldex Therapeutics, Inc. (NASDAQ:CLDX), quarterly performance is -34.70%.
On June 07, 2014, CytRx Corporation (NASDAQ:CYTR), recently announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas — significantly increasing progression-free survival at six months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. CytRx Corporation (NASDAQ:CYTR), shares moved up 8.45% in last trading session and was closed at $4.75, while trading in range of $4.41 – 4.86. CytRx Corporation (NASDAQ:CYTR), year to date (YTD) performance is -24.24%.
On June 06, 2014, Exelixis, Inc. (NASDAQ:EXEL), has recently reported that it would attend a few important investor conferences at which a member of the company would be giving a presentation regarding the plans of the company for achieving long-term growth and progress. Exelixis, Inc. (NASDAQ:EXEL), ended the last trading day at $3.51. Company weekly volatility is calculated as 3.63% and price to cash ratio as 2.68. Exelixis, Inc. (NASDAQ:EXEL), showed a negative weekly performance of 7.67%.
Immunomedics, Inc. (NASDAQ:IMMU), announced that IMMU-132, the Company’s antibody-drug conjugate (ADC) for solid cancer therapy, has received orphan drug status from the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. Immunomedics, Inc. (NASDAQ:IMMU), weekly performance is 12.65%. On last trading day company shares ended up $3.74. Analysts mean target price for the company is $8.33. Immunomedics, Inc. (NASDAQ:IMMU), distance from 50-day simple moving average (SMA50) is 0.83%.